Miller DH - Search Results

1

A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis.

Chataway J, Nicholas R, Todd S, Miller DH, Parsons N, Valdés-Márquez E, Stallard N, Friede T. Chataway J, et al. Among authors: miller dh. Mult Scler. 2011 Jan;17(1):81-8. doi: 10.1177/1352458510382129. Epub 2010 Aug 26. Mult Scler. 2011. PMID: 20798135

2

Natalizumab therapy for multiple sclerosis.

Chataway J, Miller DH. Chataway J, et al. Among authors: miller dh. Neurotherapeutics. 2013 Jan;10(1):19-28. doi: 10.1007/s13311-012-0171-4. Neurotherapeutics. 2013. PMID: 23307290 Free PMC article. Review.

3

Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial.

Kapoor R, Furby J, Hayton T, Smith KJ, Altmann DR, Brenner R, Chataway J, Hughes RA, Miller DH. Kapoor R, et al. Among authors: miller dh. Lancet Neurol. 2010 Jul;9(7):681-8. doi: 10.1016/S1474-4422(10)70131-9. Epub 2010 Jun 8. Lancet Neurol. 2010. PMID: 20621711 Clinical Trial.

4

Multiple sclerosis-quenching the flames of inflammation.

Chataway J, Miller DH. Chataway J, et al. Among authors: miller dh. Lancet. 2011 Nov 19;378(9805):1759-60. doi: 10.1016/S0140-6736(11)61133-1. Epub 2011 Oct 31. Lancet. 2011. PMID: 22047970 No abstract available.

5

Spinal cord atrophy as a primary outcome measure in phase II trials of progressive multiple sclerosis.

Cawley N, Tur C, Prados F, Plantone D, Kearney H, Abdel-Aziz K, Ourselin S, Wheeler-Kingshott CAG, Miller DH, Thompson AJ, Ciccarelli O. Cawley N, et al. Among authors: miller dh. Mult Scler. 2018 Jun;24(7):932-941. doi: 10.1177/1352458517709954. Epub 2017 May 18. Mult Scler. 2018. PMID: 28516804

6

Overview of London trial of intramuscular interferon-beta Ia in primary-progressive multiple sclerosis.

Miller DH, Leary SM, Thompson AJ. Miller DH, et al. Mult Scler. 2004 Jun;10 Suppl 1:S56-7. doi: 10.1191/1352458504ms1031oa. Mult Scler. 2004. PMID: 15218810 Review.

7

Investigation of outer cortical magnetisation transfer ratio abnormalities in multiple sclerosis clinical subgroups.

Samson RS, Cardoso MJ, Muhlert N, Sethi V, Wheeler-Kingshott CA, Ron M, Ourselin S, Miller DH, Chard DT. Samson RS, et al. Among authors: miller dh. Mult Scler. 2014 Sep;20(10):1322-30. doi: 10.1177/1352458514522537. Epub 2014 Feb 19. Mult Scler. 2014. PMID: 24552746

8

Grey matter involvement by focal cervical spinal cord lesions is associated with progressive multiple sclerosis.

Kearney H, Miszkiel KA, Yiannakas MC, Altmann DR, Ciccarelli O, Miller DH. Kearney H, et al. Among authors: miller dh. Mult Scler. 2016 Jun;22(7):910-20. doi: 10.1177/1352458515604905. Epub 2015 Oct 2. Mult Scler. 2016. PMID: 26432854

9

White matter tract abnormalities are associated with cognitive dysfunction in secondary progressive multiple sclerosis.

Meijer KA, Muhlert N, Cercignani M, Sethi V, Ron MA, Thompson AJ, Miller DH, Chard D, Geurts JJ, Ciccarelli O. Meijer KA, et al. Among authors: miller dh. Mult Scler. 2016 Oct;22(11):1429-1437. doi: 10.1177/1352458515622694. Epub 2016 Jan 5. Mult Scler. 2016. PMID: 26733423

10

Advancing trial design in progressive multiple sclerosis.

Miller DH, Thompson AJ. Miller DH, et al. Mult Scler. 2017 Oct;23(12):1571-1572. doi: 10.1177/1352458517729767. Mult Scler. 2017. PMID: 29041869 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,171 results

Search Page

Filters